Nothing for something: Marketing cancer drugs to physicians increases prescribing without improving mortality
本摘要源自该文的 NBER 工作论文版（2024），正式发表版可能有调整。
Physicians commonly receive marketing-related transfers from drug firms.We examine the impact of these relationships on the prescribing of physician-administered cancer drugs in Medicare.We find that prescribing of the associated drug increases 4\% in the twelve months after a payment is received, with the increase beginning sharply in the month of payment and fading out within a year.A marketing payment also leads physicians to begin treating cancer patients with lower expected mortality.While payments result in greater expenditure on cancer drugs, there are no associated improvements in patient mortality.